Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Small observational reports and case series suggest some patients may tolerate combined therapy, but outcomes are inconsistent and confounded by diet, exercise, and baseline metabolic status
Jan-Jun 2015;6(1):40-8
The primary contraindication is a personal history of cancer, since its growth hormone-stimulating mechanism is not appropriate for patients with any oncological history
You can get labs done by your primary doctor
2024;30:e944436
Phase I Safety Profile: While topical and low-dose injectable formulations demonstrate high tolerance and minimal systemic toxicity, there is no formal Phase I safety data for chronic 85 mg/day intranasal delivery in humans
US$ 29.19
US$ 28.31
US$ 28.17
